JERUSALEM--(BUSINESS WIRE)--May 8, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that COPAXONE® (glatiramer acetate injection), the #1 global therapy for relapsing multiple ...

Teva Files Citizen Petition with the U.S. Food and Drug Administration (FDA) Regarding the Complexity of COPAXONE® (glatiramer acetate) Following the Agency's Guidance Teva includes new gene ...

Champion pool player David Krolick found himself behind the eight ball six years ago when he was diagnosed with multiple sclerosis (MS). Until doctors confirmed his illness, Krolick, 52, of ...

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office’s (EPO) Opposition Division upheld patent ...

(RTTNews) - Viatris Inc. (VTRS) announced the launch in Canada of Glatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of Teva's Copaxone 20 mg/mL, ...

A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...

Oct 12 (Reuters) - A U.S. appeals court on Friday upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd on its blockbuster multiple sclerosis drug Copaxone. The ruling was ...

ST. LOUIS--(BUSINESS WIRE)--Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results ...